TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00951223

Intervention type: DRUG
Intervention: Infergen® (Interferon alfacon-1)
Description: Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
Study: NCT04109183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Description: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Study: NCT04079387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOTRACHEAL TUBE + STYLET
Description: The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOTRACHEAL TUBE ALONE
Description: intubating the trachea with an endotracheal tube alone
Study: NCT03013257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
Study: NCT01877785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: Single-ascending dose of MHAA4549A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MHAA4549A
Study: NCT02177175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study: NCT04109183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Description: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Description: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Study: NCT02177175

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01089816

Intervention type: BIOLOGICAL
Intervention: Local/Regional Public Health Notification
Description: For any H5 positive results, notification of the result to the site's local/regional public health authorities.
Study: NCT00376246

Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe

Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe
Study: NCT02722772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 5 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 5 weeks
Study: NCT01286701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study: NCT03700268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual intervention to programme Cochlear Implant electrodes
Description: The Clinician test the 22 electrodes so that the patient is able to hear the language

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual intervention to programme Cochlear Implant electrodes
Description: The Clinician test the 22 electrodes so that the patient is able to hear the language
Study: NCT02576925

Intervention type: OTHER
Intervention: Clinical, ophthalmological and neurological evaluation
Description: Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
Study: NCT04392869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The CRAFT program (adapted due to COVID-19)
Description: The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The MBSR program (adapted due to COVID-19)
Description: The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context.
Study: NCT04671069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
Study: NCT02584816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRV-PV Lot A + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRV-PV Lot B + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRV-PV Lot C + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROTARIX + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
Study: NCT01644565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5
Study: NCT04671069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
Study: NCT04350801

Intervention type: DIAGNOSTIC_TEST
Intervention: home-based cognitive monitoring
Description: a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)

Intervention type: DIAGNOSTIC_TEST
Intervention: home-based cognitive monitoring
Description: a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
Study: NCT00480207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Study: NCT01644565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Study: NCT00480207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit B12
Study: NCT01644565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Study: NCT00480207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit B12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folic acid placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folic acid placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omega-3 placebo
Study: NCT01644565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Study: NCT00480207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omega-3 placebo
Study: NCT02456792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Women will undergo one IVF cycle
Study: NCT01644565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Study: NCT02456792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOD
Description: Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
Study: NCT01644565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Study: NCT01721148

Intervention type: DRUG
Group type: OTHER
Intervention: ASLAN002( BMS 777607)
Description: 100mg, 200mg, 300mg, 450mg, 600mg
Study: NCT01256983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: 10000 Lux for 30 Minutes according to sleep wake rhythm

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list intervention
Description: 10000 Lux for 30 Minutes according to sleep wake rhythm
Study: NCT03957746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
Study: NCT05529407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple Vaginal Tampon
Description: Use of single use vaginal tampons

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass Vaginal Trainer
Description: Use of glass vaginal trainers
Study: NCT03429738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets
Description: Experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets
Description: Active Comparator
Study: NCT00589173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record (IPHR)
Description: Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard preventive care
Description: Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
Study: NCT02059629

Intervention type: DEVICE
Intervention: Eluna pacemaker family
Description: New pacemaker generation with new functions, like wandless RF telemetry SafeSync

Intervention type: DEVICE
Intervention: Sentus BP lead
Description: over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
Study: NCT00780949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal biopsies
Description: intestinal biopsies during routine endoscopy
Study: NCT00529100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Phase 1
Description: 300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
Study: NCT03957746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
Study: NCT01875913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curiosity Message
Description: Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Message
Description: Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online).
Study: NCT01174888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Drug midostaurin, Given orally given twice daily days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Drug midostaurin, Given orally given twice daily days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib given IV on days 1, 4, 8, and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib given IV on days 1, 4, 8, and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Patients receive mitoxantrone hydrochloride IV over 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Patients receive etoposide IV over 1 hour
Study: NCT03840616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VT-1161) 150mg capsule
Description: 600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 150mg capsule
Description: 150mg administered every 72 hours in 3 sequential doses starting on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered once weekly starting on Day 14.
Study: NCT01174888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Patients receive cytarabine IV over 6 hours on days 1-6
Study: NCT03030768

Intervention type: DRUG
Intervention: PrEP
Description: An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.

Intervention type: BEHAVIORAL
Intervention: Counseling on timed condomless sex, ART and PrEP adherence
Description: An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
Study: NCT00270413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU11248
Description: sutent 50 mg daily 4w on 2w off
Study: NCT03123510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium spp plus bimuno- galacto-oligosaccharides
Description: Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
Study: NCT00690976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proyecto SOL
Description: Group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCT
Description: Offer of HIV counseling and testing
Study: NCT00520286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg or 400 mg /daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo / daily
Study: NCT01908816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
Study: NCT02114476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: progestin implant
Description: two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00529100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Phase 1
Description: Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phases 1 and 2: 61-65 Gy in 33-35 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phases 1 and 2: 61-65 Gy in 33-35 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Phase 2
Description: Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
Study: NCT04100785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy
Description: The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
Study: NCT02468752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Air
Study: NCT03908762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSage App with connected glucometer
Description: Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Magnet
Description: Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
Study: NCT00778024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine HCL 40 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine HCL 40 mg capsules
Study: NCT02633488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A 12 week single blind placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: A 12 week single blind metformin
Study: NCT04300010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Topical Benzoyl Peroxide Gel
Description: Gel treatment used to treat acne

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Topical Benzoyl Peroxide Gel
Description: Gel treatment used to treat acne

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light Therapy
Description: Blue light therapy treatment for acne

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light Therapy
Description: Blue light therapy treatment for acne
Study: NCT01305148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warfarin GenoSTAT Test
Description: Use of genetic information from the GenoSTAT test to determine the warfarin dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warfarin GenoSTAT Test
Description: Use of genetic information from the GenoSTAT test to determine the warfarin dose
Study: NCT02267278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
Study: NCT01201707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Description: Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
Study: NCT03108625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.